Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Confavreux C, Li DK, Freedman MS, Truffinet P, Benzerdjeb H, Wang D, Bar-Or A, Traboulsee AL, Reiman LE, O'Connor PW, et al. Mult Scler. 2012 Sep; 18(9):1278-89. Epub 2012 Feb 03. PMID: 22307384. Abstract CommentRecommendBookmarkWatch